EndLyz Therapeutics

$20.5Mtotal raised · 2 rounds on record
$17.3Mlatest round · Venture round · Mar 2026 · 7 mo ago
1backers · Oxford Science Enterprises
50+team · employees, estimated range

Overview

Targeting endo-lysosomal dysfunction for the treatment of dementia. 8.5.

Funding and backers

Total raised
$20.5M
2 rounds on record
Latest round
$17.3M
Venture round · Mar 2026 · 7 mo ago
Team
51-200
employees, estimated range
Backers
1
Oxford Science Enterprises
The money's age
Fresh money
7 months since the last round · not hiring
Momentum
20/100
fresh money
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Mar 31 Raised a round Venture round $17.3M · SEC Form D Jul 16, 2021 Raised a round Venture round $3.3M · SEC Form D
Funding rounds
RoundDateAmountInvestorsSource
Venture round Mar 2026 $17.3M — SEC Form D
Venture round Jul 2021 $3.3M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity Endlyz Therapeutics, Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Joanna WolakExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Oxford Science Enterprises fund
Investors in similar startupsfunds that back the companies most like this one
High-Tech Gründerfonds
backs Mediaire
Speedinvest
backs Five Lives
Headline
backs Five Lives
IBB Ventures
backs Mediaire
Aisling Capital
backs RyCarma Therapeutics
Kurma Partners
backs RyCarma Therapeutics
Similar startupsby what they do, their industry and backers
Kneu HealthVenture round · 5 mo ago · Founded 2022
Kneu Health transforms smartphones into smarter neurology care platforms, detecting Parkinson’s and dementia earlier to ease system…
BrainFx
Measure Milder Cognitive Dysfunction and Plan More Targeted Care.
RyCarma TherapeuticsFounded 2024
Targeting RyR. A novel mechanism to correct calcium channel dysfunction.
Five LivesFounded 2021 · 51-200 employees
Add life to years by fighting Alzheimer’s & other forms of dementia. Personalized brain health plan to improve your lifestyle and cognitive…
Introducing Keenova and Par HealthVenture round $170.6M · 2 yr ago · Founded 2023 · 201-500 employees
Mallinckrodt and Endo are merging to create a leading global therapeutics company with branded and generic products. Stay tuned for updates.
Diasome PharmaceuticalsVenture round $3.1M · 2 yr ago · 51-200 employees
Diasome’s HDV™ platform redefines drug delivery by targeting the liver, improving treatment for diabetes, obesity, and metabolic…

Financials

Total raised
$20.5M
Latest round
Venture - Series Unknown
Funding rounds
2
Funding rounds
Round Announced Amount
Venture - Series Unknown 2026 $17.3M Details
Venture - Series Unknown 2021 $3.3M Details

People

Joanna Wolak
Executive Officer, Director
SEC Form D
Timothy Edwards
Director
SEC Form D
Donmienne Leung
Director
SEC Form D
Laurence Barker
Director
SEC Form D
Justian Fox
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Connections

List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors1
Oxford Science EnterprisesVia a fund
81 portfolio companies: First Light Fusion, Archangel Lightworks, Alloyed and 78 more
Report a mistake

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Boston United States
HQ
50-200 est. staff